<ѻý>Can Late-Stage Cancer Incidence Serve as an Endpoint for Screening Trials?ѻý> Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all Apr 08, 2024
<ѻý>Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancersѻý> About half of patients responded, duration of response as long as 19 months in three trials Apr 05, 2024
<ѻý>Forget 'Pack-Years' for Lung Cancer Screening Eligibility, Study Suggestsѻý> Switching to just a 20-year duration of smoking could catch more cancers, eliminate disparities Apr 01, 2024
<ѻý>Graphic Images on Cigarettes of Smoking's Harm Are Constitutional, Court Rulesѻý> Partial victory for federal regulators seeking to toughen warning labels Mar 22, 2024
<ѻý>EPA Bans Asbestos, a Deadly Carcinogen Still in Use Decades After Partial Banѻý> New rule would prohibit chrysotile asbestos Mar 19, 2024
<ѻý>First-Line Immunotherapy Alone Sufficient for Older NSCLC Patients, Study Suggestsѻý> Retrospective analysis finds similar OS, PFS whether or not patients also received chemotherapy Mar 07, 2024
<ѻý>FDA OKs Amivantamab as First-Line Lung Cancer Treatmentѻý> Bispecific drug lands full approval for NSCLCs with EGFR exon 20 insertion mutations Mar 04, 2024
<ѻý>Changing the Surgical Paradigm in Oligometastatic NSCLCѻý> Propensity-score matched analysis suggests survival benefit with surgery to the primary tumor Feb 23, 2024
<ѻý>Another COVID Toll: Over 134,000 Undiagnosed Cancers During Height of Pandemicѻý> Diagnosis rates remained low throughout 2020, with mortality increase projected Feb 22, 2024
<ѻý>Arginine Starvation Boosts OS in Mesotheliomaѻý> With frontline immunotherapy now standard, strategy could potentially find home in second-line Feb 16, 2024
<ѻý>Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLCѻý> But how well will the results from China translate to Western populations? Feb 16, 2024
<ѻý>Tepotinib Gains Full Approval for Metastatic NSCLCѻý> Agency converts accelerated approval for subset with MET exon 14 mutations Feb 16, 2024
<ѻý>Smokers Who Quit and Stick With It See Greatest Reduction in Cancer Riskѻý> Cessation at any age proved helpful for lowering cancer risk Feb 06, 2024
<ѻý>Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugsѻý> "If the patients are not taking the drug, then it's not going to work" Feb 06, 2024
<ѻý>Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Saysѻý> Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
<ѻý>Pushback on Rule for Surgical Lymph Node Sampling During Lung Resectionѻý> Surgeons debate the right standard for lymph node dissection in lung cancer Jan 31, 2024
<ѻý>How Can Cancer Risk Be Cut in Communities Exposed to Toxins?ѻý> Group outlines plan to bring the latest testing and treatment to medically underserved minorities Jan 25, 2024
<ѻý>EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Riskѻý> Findings don't tell us to stop these drugs, researcher says, but should guide clinical decisions Jan 13, 2024
<ѻý>Hypofractionated Chemoradiation With Adaptive SABR Appeared Effective in NSCLCѻý> Dose of 70 Gy in 15 fractions showed favorable balance between safety and efficacy in small trial Jan 12, 2024
<ѻý>Cryobiopsy and Forceps Biopsy Go Head-to-Head for Diagnosing Lung Lesionsѻý> When added to needle aspiration, one method yielded better samples for molecular testing in NSCLC Jan 09, 2024
<ѻý>Futile Immunotherapy for Cancer Grows More Commonѻý> Occurs most often at non-academic and low-volume centers Jan 04, 2024
<ѻý>Cancer Patients Face Frightening Delays in Treatment Approvalsѻý> "For them to take weeks -- up to months -- to provide an authorization is ridiculous" Dec 30, 2023
<ѻý>Homelessness Tied to Worse Cancer Outcomes Among Veteransѻý> However, all-cause mortality rates in lung, colon cancer lower versus other healthcare settings Dec 21, 2023
<ѻý>Grappling With Our Deadliest Cancerѻý> Here are essential steps to improve lung cancer screening Dec 10, 2023
<ѻý>With an Old X-Ray, AI Can Detect High Risk of Lung Cancer in Never Smokersѻý> Tool could identify nonsmokers most likely to benefit from low-dose CT screening Nov 29, 2023
<ѻý>Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutationsѻý> Researchers suggest the drug is a promising option for this rare subgroup Nov 22, 2023
<ѻý>FDA OKs New Option for Advanced ROS1-Positive Lung Cancerѻý> Drug achieved high response rates in TKI-naive and TKI-pretreated patients Nov 16, 2023
<ѻý>Lung Cancer Survival High at 20 Years With Screen-Detected Tumorsѻý> After two decades, lung cancer-specific survival remained at 81% in I-ELCAP program Nov 07, 2023
<ѻý>Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S.ѻý> Findings suggest patients with SCLC are not screened for LEMS, despite their association Nov 02, 2023
<ѻý>ACS: Millions More Should Get Lung Cancer Screeningѻý> Notably, new recommendations say it doesn't matter when a person quit smoking Nov 01, 2023
<ѻý>The Exciting Potential of Antibody-Drug Conjugates in Lung Cancerѻý> Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3 Oct 30, 2023 video
<ѻý>New Options Challenge Standard Treatments in EGFR-Mutant NSCLCѻý> Amivantamab-based regimens improved oncologic outcomes, but with more side effects Oct 25, 2023
<ѻý>ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancerѻý> Adjuvant alectinib reduces disease-free survival hazard by 76% Oct 24, 2023
<ѻý>Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancersѻý> Still some unanswered questions about benefit over other drug regimens, expert says Oct 24, 2023
<ѻý>Targeting KRAS in NSCLC: Recent Progress and New Approachesѻý> Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available Oct 23, 2023 video
<ѻý>New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertionsѻý> Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
<ѻý>RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLCѻý> Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
<ѻý>Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyondѻý> Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
<ѻý>Pembrolizumab Wins FDA Approval in Operable Lung Cancerѻý> Checkpoint inhibitor demonstrated significant survival improvement in perioperative setting Oct 17, 2023
<ѻý>New Lung Cancer Cases Are Higher in Younger Women vs Menѻý> And the higher incidence rates now extend to women ages 50 to 54 as well Oct 12, 2023